Title:
Lapatinib (Tyverb) is not recommended for use within NHS Scotland
Excerpt:CONTRADICTING EVIDENCE: Lapatinib (Tyverb) is not recommended for use within NHS Scotland...in combination with capecitabine, for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress ErbB2 (HER2) and who have progressive disease...
Excerpt:TYKERB is a kinase inhibitor indicated in combination with:...capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab...
Excerpt:Tyverb is indicated for the treatment of patients with breast cancer, whose tumours overexpress HER2 (ErbB2):...in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy…
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib
Excerpt:...Metastatic breast cancer that over-expresses ErbB2 (3+ by IHC; FISH or CISH positive)and the subject has received prior therapy including an anthracycline, a taxane, and trastuzumab OR Recurrent, advanced, or metastatic solid tumor malignancy (including breast cancer that does...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Exploratory Lapatinib (Positron Emission Tomography) PET Study in Subjects With Breast Cancer
Excerpt:...- Advanced or metastatic breast cancer with overexpression of HER2...
More C2 evidence
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer
Excerpt:...- Have histologically or cytologically confirmed ErbB2-overexpressing invasive carcinoma (TX or T1-4) of the breast at the time of the initial diagnosis and have undergone adequate excision of tumor;...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery
Excerpt:...HER2-positive is defined as HER2 overexpression and/or amplification as determined by immunohistochemistry (3+) or fluorescence in situ hybridization (FISH) (>= 2.0)...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer
Excerpt:...- Unequivocal ErbB2 overexpressing breast cancer, defined as 3+ staining by immunohistochemistry (IHC), or 2+ staining by IHC in conjunction with ErbB2 gene amplification by FISH/CISH, or ErbB2 gene amplification by FISH/CISH alone (in subjects whose tumor blocks were...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Neoadjuvant GW572016 to Treat Breast Cancer
Excerpt:...HER2 overexpressing tumors defined as HercepTest score of 3+, or >/- 10% cells moderately or strongly HER2 positive by other methods, or semi-quantitative score of >/- 5 (in Dr. ...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast Cancer
Excerpt:...- Subjects must meet the following criteria regarding ErbB2 expression (defined by the following status before undergoing trastuzumab therapy.) Patients with ErbB2 overexpression:...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
GW572016 In Patients With Advanced Or Metastatic Breast Cancer
Excerpt:...To evaluate tumor response rate in both cohort A (ErbB2 overexpressors) and in cohort B (ErbB2 non-overexpressor) population when treated with GW572016...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients
Excerpt:...- Metastatic, histologically confirmed breast cancer that over-expresses ErbB2 (3+ by IHC; FISH or CISH positive)....
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Drug Use Investigation for TYKERB Tablet (All Case Investigation)
Excerpt:...- Patients with HER2 overexpressing inoperable or recurrent breast cancer...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval
Excerpt:...Metastatic breast cancer that over-expresses ErbB2 OR Recurrent, advanced, or metastatic solid tumor malignancy (including breast cancer that does...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer
Excerpt:...Subjects that have documented ErbB2 amplification based on prior FISH testing or documented ErbB2 overexpression based on prior immunohistochemistry (IHC) with a value of 3+ are eligible, however, archived tumor tissue must be provided for confirmation by the central laboratory....
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
The Myocet/Lapatinib Study. ICORG 10-03, V5
Excerpt:...Documented HER2 overexpression (IHC 3+ or FISH or CISH positive) 5....
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer
Excerpt:...- Tumor that overexpresses ErbB2 defined as 3+ by IHC or FISH +....
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2
Excerpt:...- Tumor HER2 overexpression...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer
Excerpt:...- HER2 overexpressing breast cancer defined as 3+ staining by immunohistochemistry, or HER2 gene amplification by FISH...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases
Excerpt:...- HER2 overexpressing breast cancer, defined as 3+ staining by immunohistochemistry (IHC), or 2+ staining by IHC in conjunction with HER2 gene amplification by fluorescent in situ hybridization (FISH), or HER2 gene amplification by FISH alone (in patients whose tumor blocks were...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer
Excerpt:...- HER2-overexpressing breast cancer (3+ staining by immunohistochemistry or HER2 gene amplification by fluorescent in situ hybridization [FISH] or silver in situ hybridization [SISH] >= 2.0)...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
INST 0514C- Biologic Correlative Study: Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients
Excerpt:...HER2 overexpressing tumors defined as HercepTest score of 3+, or > 10% cells moderately or strongly HER2 positive by other methods, or semi-quantitative score of >5 (in Dr. ...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Lapatinib and Bevacizumab for Metastatic Breast Cancer
Excerpt:...- Documented evidence of HER2-overexpressing unresectable or metastatic breast cancer....
